DDIT3 and lymphoma: However, the phase 3 AMC010 study comparing CHOP and R‐CHOP showed that addition of rituximab to chemotherapy improves the CR rate in HIV‐associated lymphoma patients (58% vs. 47%), although no difference was found in PFS or OS.